{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 11,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/7",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.23,
        "w": 0.62,
        "x": 0.32,
        "y": 0.63
      },
      "kind": "diagram",
      "text": "2:1 Randomization VYD222 4500 mg IV (n=300) Day 1 (Dosing) Placebo IV (n=150) Month 3 (Redosing) Month 12 (Last visit)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49b9a0e8-8740-4a89-abe8-acf05afcbc68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.62,
        "x": 0.32,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Open Label VYD222 4500 mg IV (n=300) Day 1 (Dosing) Day 28 (Primary efficacy endpoint) Month 3 (Redosing) Month 12 (Last visit)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65a25ad2-f4dd-4663-8659-58e7cbbeacae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.159,
        "w": 0.269,
        "x": 0.045,
        "y": 0.69
      },
      "kind": "list",
      "text": "COHORT B At risk of SARS-CoV-2 exposure (N=450) Primary endpoint: Safety/tolerability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d9c17c3-5bc1-44a4-a853-238f423afcd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.259,
        "w": 0.269,
        "x": 0.045,
        "y": 0.315
      },
      "kind": "list",
      "text": "COHORT A Immunocompromised (N=300) Primary endpoints: Safety/tolerability Day 28 serum neutralizing titers (calculated from the pharmacokinetic concentrations of VYD222 and the IC50 value for VYD222 against relevant SARS-CoV-2 variants)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe3bdfb4-fd77-46da-936f-11b147c90dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.32,
        "x": 0.045,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: ClinicalTrials.gov Identifier: NCT06039449; IV, intravenous",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "087c3502-26a4-45d2-8f94-884340d05ece",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.39,
        "x": 0.045,
        "y": 0.199
      },
      "kind": "title",
      "text": "The CANOPY clinical trial is now fully enrolled",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4af0f8f-39c1-4642-aa9c-1312a873892d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.91,
        "x": 0.045,
        "y": 0.06
      },
      "kind": "title",
      "text": "THE CANOPY PHASE 3 CLINICAL TRIAL OF VYD222 IS DESIGNED TO RAPIDLY GENERATE CLINICAL DATA FOR A POTENTIAL EUA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f467fbb-4e23-4a46-a6b9-18702ac11e0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "98297a7b-21bb-4330-add0-fea6bdafb33b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The comparison table and roadmap provide a clear visualization of VYD222's potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889",
      "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction",
      "position": 0,
      "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}